A phase II study of percutaneous trans-esophageal gastric tubing for malignant gastrointestinal obstruction (JIVROSG-0205)

A phase II study of percutaneous trans-esophageal gastric tubing for malignant gastrointestinal obstruction (JIVROSG-0205) - Percutaneous trans-esophageal gastric tubing (JIVROSG-0205)

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000249

Enrollment

Registered

2006-09-01

Start date

2003-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant gastrointestinal obstruction

Interventions

Under local anesthesia and fluoroscopy or ultrasonic guidance, a percutaneous route to cervical esophagus is made by direct puncture to the intra-esophageal balloon inserted via nasal or oral route, a

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) No expectation for removal of nasal tube caused by persistent and malignant gastro-intestinal obstruction. 2) No pathological condition around cervical esophagus. 3) Adequate cardiac, hepatic, renal, respiratory, and bone marrow functions. 4) Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3. 5) Expected survival more than 4 weeks. 6) Written informed consent.

Exclusion criteria

Exclusion criteria: 1) Tracheostomy. 2) Intestinal obstruction due to the lesions between transverse colon and rectum. 3) Pregnancy. 4) Local therapy for neck region

Design outcomes

Primary

Measure	Time frame
Improvement of subjective symptoms compared to previous nasal tubing.	—

Secondary

Measure	Time frame
Adverse events and feasibility of procedure	—

Countries

Japan

Contacts

Public ContactYasuaki Arai

JIVROSG, Coordinating Office Division of Diagnostic Radiology, National Cancer Center Hospital

jvrosgffice@ml.res.ncc.go.jp0335422511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026